AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1834592 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered i.v. on 2 consecutive days
Number of subjects: 8
Study 7009594 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly coated‐charcoal hemoperfusion (CCHP)
Number of subjects: 6
Study 7009594 — intervention group
Group type: COMPARATOR
Intervention: Sham hemoperfusion (Sham HP)
Number of subjects: 6
Study 30791795 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Drug Program (FDP)
Number of subjects: 2007
Study 30791795 — intervention group
Group type: COMPARATOR
Intervention: Home drug delivery
Number of subjects: 2007
Study 30791795 — intervention group
Group type: COMPARATOR
Intervention: Long-lasting injection treatment
Number of subjects: 2007
Study 28272202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia (CEGA)
Number of subjects: 144
Study 26192183 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric Mediterranean type of diet and physical activity intervention (D+PA)
Number of subjects: 342
Study 26192183 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention alone (PA)
Number of subjects: 342
Study 26192183 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 342
Study 23429100 — intervention group
Group type: EXPERIMENTAL
Intervention: N-MUF (3000 ml)
Number of subjects: 50
Study 23429100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N-MUF)
Number of subjects: 50
Study 21409669 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy-arousing messages
Number of subjects: 260
Study 21409669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-arousing messages
Number of subjects: 260
Study 21409669 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 260
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) with acidic beverage
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) with higher gastric pH
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) plus nutritional supplement (Boost)
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg) plus nutritional supplement (Boost)
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) before high-fat meal
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) during high-fat meal
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg) after high-fat meal
Number of subjects: 0
Study 19075045 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased gastric motility
Number of subjects: 0
Study 17488963 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 201
Study 17488963 — intervention group
Group type: COMPARATOR
Intervention: Intensive anti-ischemic drug therapy
Number of subjects: 201
Study 15535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized social phobia participants
Number of subjects: 0
Study 15535796 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 11133616 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile Soft-Seal Cuff (PSSC)
Number of subjects: 45
Study 11133616 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile Cuff (PC)
Number of subjects: 45
Study 11133616 — intervention group
Group type: COMPARATOR
Intervention: Trachelon
Number of subjects: 45
Study 9439908 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment
Number of subjects: 200
Study 9439908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7533703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30mg
Number of subjects: 126
Study 7533703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60mg
Number of subjects: 126
Study 7533703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 2962993 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 2962993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29529650 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 101
Study 29529650 — intervention group
Group type: COMPARATOR
Intervention: Miniposterior Approach (MPA)
Number of subjects: 101
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dyspnea improvement measured by Likert scale during the first 24 hours
Number of subjects: 1161
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea improvement over the first 5 days measured by visual analog scale area under the curve (VAS AUC)
Number of subjects: 1161
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: General wellbeing improvement measured by Likert scale
Number of subjects: 1161
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: General wellbeing improvement measured by VAS score
Number of subjects: 1161
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-variable predictors of moderate or marked dyspnea improvement
Number of subjects: 1161
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy of serelaxin
Number of subjects: 1161
Study 27838739 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital and post-discharge clinical outcomes
Number of subjects: 1161
Study 26328771 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training intervention to improve patient engagement in activities
Number of subjects: 0
Study 23146135 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 6 months
Number of subjects: 50
Study 21513078 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive alveolar recruitment strategy (ARS) with 10 manual breaths at 40 cmH2O and PEEP of 15 cmH2O until OLV commenced.
Number of subjects: 42
Study 21513078 — intervention group
Group type: COMPARATOR
Intervention: Control group with tidal volume of 10 ml kg(‐1).
Number of subjects: 42
Study 18313637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use
Number of subjects: 422
Study 18313637 — intervention group
Group type: COMPARATOR
Intervention: Male condom use
Number of subjects: 422
Study 18313637 — intervention group
Group type: COMPARATOR
Intervention: No contraceptive method
Number of subjects: 422
Study 16239594 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)
Number of subjects: 309
Study 16239594 — intervention group
Group type: COMPARATOR
Intervention: None (control group: women without T2DM or MS)
Number of subjects: 309
Study 16239594 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS) alone
Number of subjects: 309
Study 12611772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 8
Study 12611772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-rich protein supplementation
Number of subjects: 8
Study 12611772 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study 10390376 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppb O3
Number of subjects: 11
Study 10390376 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb NO2
Number of subjects: 11
Study 10390376 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppb O3 + 200 ppb NO2
Number of subjects: 11
Study 10390376 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb O3
Number of subjects: 11
Study 10390376 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb NO2
Number of subjects: 11
Study 10390376 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb O3 + 400 ppb NO2
Number of subjects: 11
Study 10390376 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 11
Study 8862681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of cisplatin
Number of subjects: 0
Study 8862681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0
Study 1712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 5,000 IU hCG
Number of subjects: 24
Study 1712735 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of 5,000 IU hCG
Number of subjects: 24
Study 6131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway cooling during exercise
Number of subjects: 0
Study 6131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory heat exchange
Number of subjects: 0
Study 6131223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast-cell mediators
Number of subjects: 0
Study 30507241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Coach (VC) condition
Number of subjects: 32
Study 30507241 — intervention group
Group type: COMPARATOR
Intervention: Standard Coach + VR condition
Number of subjects: 32
Study 27418129 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 37
Study 27418129 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 37
Study 25470087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole long-acting injection (LAI)
Number of subjects: 0
Study 25470087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23872254 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng extract (RGE) 1500 mg orally three times a day for 7 days
Number of subjects: 15
Study 19965813 — intervention group
Group type: EXPERIMENTAL
Intervention: Reg6M (6-month regimen: 2EHRZ(3)/4HR(3))
Number of subjects: 327
Study 19965813 — intervention group
Group type: COMPARATOR
Intervention: Reg9M (9-month regimen: 2EHRZ(3)/7HR(3))
Number of subjects: 327
Study 18759293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab plus MTX
Number of subjects: 237
Study 18759293 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 237
Study 18759293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (doses of 200 mg and higher) plus MTX
Number of subjects: 237
Study 18759293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (10 mg and 50 mg)
Number of subjects: 237
Study 15710271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dietary feedback, brief telephone counseling, nutritional education booklets
Number of subjects: 754
Study 15710271 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 754
Study 14523139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 1058
Study 14523139 — intervention group
Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 1058
Study 10757543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in alpha-linolenic acid (8.3 g/d)
Number of subjects: 12
Study 10757543 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in oleic acid
Number of subjects: 12
Study 8922306 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine supplementation (600 mg daily for 3-9 months)
Number of subjects: 33
Study 8922306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N-acetylcysteine supplementation)
Number of subjects: 33
Study 1311872 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-cuff group (7 cm from the dentate line)
Number of subjects: 16
Study 1311872 — intervention group
Group type: COMPARATOR
Intervention: Minimum-cuff group (2 cm cuff above the levator)
Number of subjects: 16
Study 4002807 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg muzolimine once daily
Number of subjects: 53
Study 4002807 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg indapamide once daily
Number of subjects: 53
Study 31797880 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration (HDF)
Number of subjects: 32
Study 31797880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rexsys and VIE-A in both HD and HDF
Number of subjects: 32
Study 31797880 — intervention group
Group type: EXPERIMENTAL
Intervention: All dialyzers
Number of subjects: 32
Study 31797880 — intervention group
Group type: COMPARATOR
Intervention: TDC vs PDC
Number of subjects: 32
Study 31797880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rexsys
Number of subjects: 32
Study 29385054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low d‐allulose (4 g × 2 times/day)
Number of subjects: 121
Study 29385054 — intervention group
Group type: EXPERIMENTAL
Intervention: High d‐allulose (7 g × 2 times/day)
Number of subjects: 121
Study 29385054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucralose, 0.012 g × 2 times/day)
Number of subjects: 121
Study 28066101 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast-levocetirizine (10 mg and 5 mg)
Number of subjects: 70
Study 28066101 — intervention group
Group type: COMPARATOR
Intervention: Montelukast-fexofenadine (10 mg and 120 mg)
Number of subjects: 70
Study 24702629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 528
Study 24702629 — intervention group
Group type: COMPARATOR
Intervention: Usual care (unfractionated heparin or placebo)
Number of subjects: 528
Study 24331776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight management program
Number of subjects: 88
Study 21175438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 0
Study 21175438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe with dalcetrapib
Number of subjects: 0
Study 21175438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib with ezetimibe
Number of subjects: 0
Study 21175438 — intervention group
Group type: COMPARATOR
Intervention: Dalcetrapib alone
Number of subjects: 0
Study 21175438 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe alone
Number of subjects: 0
Study 18769692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-directed care
Number of subjects: 2060
Study 18769692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist collaborative care
Number of subjects: 2060
Study 16427490 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg methylprednisolone acetate and 10 mg bupivacaine
Number of subjects: 598
Study 16427490 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (oral antivirals and analgesics)
Number of subjects: 598
Study 14650210 — intervention group
Group type: EXPERIMENTAL
Intervention: mexidol, intravenously instilled in a daily dose of 2‐4 mg/kg over a period of 10 days in combination with a standard neurometabolic scheme
Number of subjects: 90
Study 10929903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis with active inflammation
Number of subjects: 62
Study 10929903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis in remission
Number of subjects: 62
Study 10929903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis with dysplasia
Number of subjects: 62
Study 10929903 — intervention group
Group type: COMPARATOR
Intervention: Controls (normal colonoscopy)
Number of subjects: 62
Study 9459674 — intervention group
Group type: EXPERIMENTAL
Intervention: oligoantigenic diet
Number of subjects: 21
Study 1632718 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 18
Study 1632718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 4061344 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of selenite
Number of subjects: 200
Study 4061344 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of yeast-Se
Number of subjects: 200
Study 4061344 — intervention group
Group type: COMPARATOR
Intervention: No Se supplements (control)
Number of subjects: 200
Study 31050933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (DL) as an adjunct to Kirkland flap surgery
Number of subjects: 20
Study 31050933 — intervention group
Group type: COMPARATOR
Intervention: Kirkland flap surgery alone
Number of subjects: 20
Study 29179625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric malaria vaccine trial (GSK/PATH‐MVI RTS,S)
Number of subjects: 52
Study 29179625 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of research into health care services
Number of subjects: 52
Study 29179625 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of research
Number of subjects: 52
Study 27036101 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education with fever education brochures
Number of subjects: 160
Study 27036101 — intervention group
Group type: COMPARATOR
Intervention: Brochure only (Control group)
Number of subjects: 160
Study 25243680 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP/START medication intervention
Number of subjects: 359
Study 25243680 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmaceutical care
Number of subjects: 359
Study 22526437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 90
Study 22526437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lidocaine 20 mg and nitroglycerin 0.1 μg/kg
Number of subjects: 90
Study 22526437 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study 20952014 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Impact Questionnaire
Number of subjects: 597
Study 20952014 — intervention group
Group type: EXPERIMENTAL
Intervention: International Consultation on Incontinence Questionnaire
Number of subjects: 597
Study 17610056 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (24‐h infusion of 0.1 mug/kg/min)
Number of subjects: 63
Study 18444445 — intervention group
Group type: EXPERIMENTAL
Intervention: LDFA (70‐100 microg/kg)
Number of subjects: 60
Study 18444445 — intervention group
Group type: EXPERIMENTAL
Intervention: IDFA (23‐30 microg/kg)
Number of subjects: 60
Study 18444445 — intervention group
Group type: EXPERIMENTAL
Intervention: SDFA (2‐4 microg/kg)
Number of subjects: 60
Study 15363826 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-atorvastatin combination
Number of subjects: 45
Study 15363826 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 45
Study 15363826 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 45
Study 11327507 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-marker imaging system measuring rotational axis pathway (RAP)
Number of subjects: 10
Study 9143085 — intervention group
Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 14
Study 9143085 — intervention group
Group type: COMPARATOR
Intervention: EasiCath catheter
Number of subjects: 14
Study 8194616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC), 100 mg from days 2 to 6
Number of subjects: 30
Study 8194616 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle (no treatment)
Number of subjects: 30
Study 3538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg orally every 12 hours
Number of subjects: 68
Study 3538962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 68
Study 30711429 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education with videos and leaflets
Number of subjects: 144
Study 30711429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 144
Study 28758127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate use of diagnostic tests and treatment of bronchiolitis
Number of subjects: 303
Study 28758127 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis
Number of subjects: 303
Study 28758127 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 303
Study 28758127 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of siblings
Number of subjects: 303
Study 27771572 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of d-Cycloserine (DCS)
Number of subjects: 51
Study 27771572 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo capsule
Number of subjects: 51
Study 24825029 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (n=143)
Number of subjects: 280
Study 24825029 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based intervention (n=137)
Number of subjects: 280
Study 21438101 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurines (azathioprine and 6-mercaptopurine)
Number of subjects: 43
Study 18691705 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 33
Study 18691705 — intervention group
Group type: COMPARATOR
Intervention: Simple sugars
Number of subjects: 33
Study 17210332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/fentanyl
Number of subjects: 46
Study 17210332 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 46
Study 16322383 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of recombinant human GH (rhGH) at 0.2 IU/kg per week
Number of subjects: 30
Study 16322383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12087344 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (single dose 900 mg)
Number of subjects: 3
Study 12087344 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (long-term treatment 300 mg 3 times a day)
Number of subjects: 3
Study 12087344 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine (untreated phase)
Number of subjects: 3
Study 9464430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m tetrofosmin scintimammography
Number of subjects: 44
Study 9464430 — intervention group
Group type: COMPARATOR
Intervention: Plain‐film mammography
Number of subjects: 44
Study 8591802 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 8
Study 8591802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2612091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporin A (CyA)
Number of subjects: 10
Study 2612091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 343062 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 0